中国实用神经疾病杂志2024，Vol.27Issue(8)：1053-1056,4.DOI:10.12083/SYSJ.231124
心源性脑卒中的心房颤动患者新型口服抗凝药治疗时机的研究进展
Research progress on timing of DOAC initiation after acute ischemic stroke in patients with atrial fibrillation
摘要
Abstract
Atrial fibrillation is the most common persistent arrhythmia with high morbidity and mortality.With the continuous progress of population aging,atrial fibrillation has become a"social epidemic".In patients with atrial fibrillation,blood is easy to form thrombus due to the loss of atrial contractile function.If the thrombus falls off,it can follow the blood to the whole body,resulting in cerebral embolism,limb artery embolism,etc.Acute ischemic stroke is one of the complications of atrial fibrillation,with a high rate of disability and mortality.The occurrence of acute ischemic stroke can be prevented by regular anticoagulant therapy in patients with atrial fibrillation.However,there is a risk of bleeding transformation during anticoagulant therapy.Therefore,this treatment is contradictory.At present,the specific time to start oral anticoagulant therapy after acute ischemic stroke in patients with atrial fibrillation is still controversial.In this review,we summarize and review the current guidelines and relevant randomized controlled studies,and describe the current research status.关键词
心房颤动/缺血性脑卒中/新型口服抗凝药(DOAC)/抗凝治疗/心源性脑卒中Key words
Atrial fibrillation/Ischemic stroke/New oral anticoagulant(DOAC)/Anticoagulant therapy/Cardiogenic stroke分类
医药卫生引用本文复制引用
汤舒洁,孙玉芳,项涛..心源性脑卒中的心房颤动患者新型口服抗凝药治疗时机的研究进展[J].中国实用神经疾病杂志,2024,27(8):1053-1056,4.基金项目
成都市卫计委科研课题(项目编号:2021217) （项目编号:2021217）
